pubmed.ncbi.nlm.nih.gov › 34423496

CYP2D6 metabolizer phenotype (ultra-rapid [UM], normal metabolizer [NM], intermediate [IM], or poor [PM]), the latter two of which may cause inefficacy of codeine, tramadol, and standard-dose hydrocodone, was determined for…

uptodate.com › contents › image › print

This table lists strong and moderate CYP450 2D6 inhibitors; there are no known clinically relevant inducers of CYP2D6. Codeine, tamoxifen, and tramadol are examples of drugs that require transformation by…

nature.com › articles › s41436-018-0431-8

Purpose. CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the ...

practicalpainmanagement.com › ... › non-responsive-pain-patients-cyp-2d6-defect

Pain patients who do not respond to the analgesic properties of opioids have a chance of being genetically incapable of generating the clinically active metabolite of these medications. Get tips…

pubmed.ncbi.nlm.nih.gov › 30670877

This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. Methods: Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided…

painphysicianjournal.com › current › pdf

exert analgesia (Fig. 2). A CYP2D6 poor metabolizer obtains hardly any pain relief from the opioid pro-drugs. For meperidine, which is an opioid drug primar-ily metabolized by CYP2D6 to an…

scholarlycommons.henryford.com › merf2019caserpt › 7

We herein report an unusual case of a poor metabolizer of medications metabolized by CYP2D6 and CYP2C19 enzymes due to genetic deficiency diagnosed on genetic testing.Case Presentation: 56 year old…

onlinelibrary.wiley.com › doi › j

In our discussion we review the literature about the clinical impact of CYP450 2D6 polymorphisms in treatment with the commonly used opioid analgesics codeine, oxycodone, hydrocodone, hydromorphone, and morphine, as…

onlinelibrary.wiley.com › doi › 10.1111 › j

Pain Practice. Volume 7, Issue 4 p. 352-356. Complicated Pain Management in a CYP450 2D6 Poor Metabolizer. Adriana Foster MD, Corresponding Author. Adriana Foster MD. Department of Psychiatry and Health…

pubmed.ncbi.nlm.nih.gov › 17986163

In our discussion we review the literature about the clinical impact of CYP450 2D6 polymorphisms in treatment with the commonly used opioid analgesics codeine, oxycodone, hydrocodone, hydromorphone, and morphine, as…

pubmed.ncbi.nlm.nih.gov › 21926528

Methods: This literature review describes the clinical and empirical evidence indicating that alterations in CYP2D6 activity can negatively affect treatment outcomes in patients receiving antidepressant pharmacotherapies that are CYP2D6 substrates.